Morepen Laboratories Limited has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately ₹825 crore (USD 91 million) from a global pharmaceutical company. The agreement represents one of the largest CDMO engagements in the company’s history and marks a significant step in expanding its global manufacturing operations.
Supplies under the contract are expected to begin within the next four to five months, with execution scheduled through the first quarter of the following financial year, subject to routine operational and regulatory clearances. The programme is designed as a structured, multi-year supply arrangement, reflecting growing demand for reliable and scalable pharmaceutical manufacturing partners.
Morepen’s entry into larger CDMO programmes builds on more than four decades of experience in active pharmaceutical ingredient (API) manufacturing. The company operates internationally accredited facilities that meet regulatory standards set by agencies including the USFDA, WHO-GMP and European authorities. Its integrated development-to-commercial manufacturing model allows it to support complex product scale-ups and long-term supply commitments for regulated markets.
Sushil Suri, Chairman and Managing Director of Morepen Laboratories, said the new mandate underscores customer confidence in the company’s manufacturing quality, regulatory track record and execution capability. He added that Morepen has steadily invested in infrastructure, compliance systems and technology to participate in larger global programmes. The CDMO business, he said, complements the company’s established API operations and creates additional avenues for sustainable growth.
Kushal Suri, President – International Growth (API), said the agreement reflects the company’s ability to meet global regulatory expectations and deliver end-to-end technical and commercial solutions. He noted that Morepen’s experience in handling complex manufacturing requirements positions it well for future global partnerships.
Pharmaceutical companies worldwide are increasingly working with fewer, trusted manufacturing partners capable of ensuring consistent supply and meeting strict regulatory standards. Morepen’s vertically integrated capabilities, global approvals and operational scale align with this trend and support its expansion into long-term development and manufacturing projects.
Morepen Laboratories Limited is a diversified pharmaceutical and healthcare company providing APIs, branded generics, medical devices and consumer wellness products in more than 90 countries. With a strong API production base, a large installed customer network in medical devices and ongoing investments in technology and compliance, the company aims to strengthen its position in global pharmaceutical manufacturing while delivering consistent value to customers and stakeholders.
